Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes.

The choice of second- and later-line options for advanced soft tissue sarcoma (aSTS) should always be considered from the patient's perspective, taking into account the potential impact of treatment on daily activities and quality of life. This review examines data on the safety of trabectedin in the management of patients with aSTS as reported in clinical trials and real-world studies. Evidence indicates that trabectedin exhibits an acceptable and manageable safety profile and is compatible with daily activities. Trabectedin is associated with low rates of toxicity-related discontinuations, few potentially life-threatening toxicities, a lack of apparent cumulative toxicities and low rates of grade 3/4 nausea, vomiting and fatigue. Trabectedin represents a valuable second-line option for aSTS, including in elderly patients.

[1]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Blay,et al.  A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Zucchetti,et al.  Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group , 2020, Cancer.

[4]  J. Blay,et al.  The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments , 2020, Expert review of anticancer therapy.

[5]  N. Araki,et al.  Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials , 2020, Cancer medicine.

[6]  Sakae Tanaka,et al.  Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study , 2019, Cancer.

[7]  Robin L. Jones.  Sarcomas and old age: few options for such a large patient population. , 2019, Future oncology.

[8]  A. Le Cesne.  Making the Best of Available Options for Optimal Sarcoma Treatment , 2018, Oncology.

[9]  Robin L. Jones,et al.  Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas , 2018, Expert review of anticancer therapy.

[10]  J. Blay,et al.  Review of past and present clinical cases with a view to future treatment options. , 2017, Future oncology.

[11]  J. Martín-Broto,et al.  Trabectedin clinical cases: use according to indication in diverse clinical scenarios. , 2015, Future oncology.

[12]  H. Earl,et al.  Trabectedin for advanced soft tissue sarcomas: a single institution experience. , 2014, Future oncology.

[13]  P. Reichardt.  Soft tissue sarcomas, a look into the future: different treatments for different subtypes. , 2014, Future oncology.

[14]  Robin L. Jones,et al.  Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.

[15]  J. Blay,et al.  Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials , 2013, British Journal of Cancer.

[16]  N. Penel,et al.  Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review , 2013, BMC Cancer.

[17]  F. Grosso,et al.  A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin , 2012, Cancer Chemotherapy and Pharmacology.

[18]  J. Blay,et al.  A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials , 2012, Investigational New Drugs.

[19]  F. Grosso,et al.  Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. , 2006, European journal of cancer.